147 related articles for article (PubMed ID: 2511277)
1. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.
Aulitzky W; Gastl G; Aulitzky WE; Herold M; Kemmler J; Mull B; Frick J; Huber C
J Clin Oncol; 1989 Dec; 7(12):1875-84. PubMed ID: 2511277
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses.
Aulitzky W; Gastl G; Aulitzky WE; Nachbaur K; Lanske B; Kemmler G; Flener R; Frick J; Huber C
Immunobiology; 1987 Dec; 176(1-2):85-95. PubMed ID: 3129362
[TBL] [Abstract][Full Text] [Related]
3. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
4. Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden.
Aulitzky WE; Lerche J; Thews A; Lüttichau I; Jacobi N; Herold M; Aulitzky W; Peschel C; Stöckle M; Steinbach F
Eur J Cancer; 1994; 30A(7):940-5. PubMed ID: 7946588
[TBL] [Abstract][Full Text] [Related]
5. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
6. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
Landmann R; Ludwig C; Wesp M; Fisscher A; Obrist R; Knüsli C; Denz H; Obrecht JP
J Interferon Res; 1992 Apr; 12(2):103-11. PubMed ID: 1374454
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
8. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
[TBL] [Abstract][Full Text] [Related]
9. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
Rinehart JJ; Malspeis L; Young D; Neidhart JA
J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma.
Ellerhorst JA; Kilbourn RG; Amato RJ; Zukiwski AA; Jones E; Logothetis CJ
J Urol; 1994 Sep; 152(3):841-5. PubMed ID: 8051732
[TBL] [Abstract][Full Text] [Related]
13. Preliminary results of the alternating administration of natural interferon-alpha and recombinant interferon-gamma for metastatic renal cell carcinoma.
Fujii A; Yui-En K; Ono Y; Yamamoto H; Gohji K; Takenaka A
BJU Int; 1999 Sep; 84(4):399-404. PubMed ID: 10468752
[TBL] [Abstract][Full Text] [Related]
14. Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha.
Aulitzky WE; Tilg H; Herold M; Berger M; Vogel W; Judmaier G; Gastl G; Mull B; Flener R; Wiegele J
J Interferon Res; 1988 Oct; 8(5):655-64. PubMed ID: 3148671
[TBL] [Abstract][Full Text] [Related]
15. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):149-53. PubMed ID: 8610639
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha.
Aulitzky WE; Aulitzky WK; Frick J; Herold M; Gastl G; Tilg H; Berger M; Huber C
Immunobiology; 1990 Jun; 180(4-5):385-94. PubMed ID: 2118879
[TBL] [Abstract][Full Text] [Related]
17. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
[TBL] [Abstract][Full Text] [Related]
18. Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma.
Sertoli MR; Brunetti I; Ardizzoni A; Falcone A; Guarneri D; Boccardo F; Martorana G; Curotto A; Sicignano A; Rosso R
Am J Clin Oncol; 1989 Feb; 12(1):43-5. PubMed ID: 2492141
[TBL] [Abstract][Full Text] [Related]
19. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
20. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
